MAY 0 2 70	(S)	Under the Paperv	ork Redu	ction Act of 1995, no persons	U.S. Patent and Trad	PTO/Se proved for use through 10/31/2002 OM lemark Office U.S. DEPARTMENT OF of information unless it contains a valid OMB	COMMERCE
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Substitut	e for form 1449A/P1	О	-		Complete if Known	50
4 DUIDENS	S. P. S.				Application Number	09/875,076	TOP'
2,1,1	INFO	RMATION	DIS	CLOSURE	Filing Date	June 6, 2001	1 VER
	STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Chen Liaw	70
7					Group Art Unit	1646 FCH	2003
		(use as many st	eets as	necessary)	Examiner Name	P Mertz	ENTED 3
7	Sheet	1	of	2	Attorney Docket Number	11.US9.DIV (AREN-0239)	1)600/20-
Ì							

_		Document Number	Publication Date	Name of Patentee or Applicant of	Pages Columns Lines, Where Relevan	
Examiner Initials *	Cite No '	Number - Kind Code ² (if known)	MM DD YYYY	Cited Document	Passages or Relevant Figures Appear	
		US-				
	Ĭ	US-				
		US-				
	Ĭ	US-				
		US-				
		US-				
]	US-				
	İ	US-				
	i	US-				
		US-				
	<u> </u>	US-				
		US-				
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-				
		us				
		US-	· · · · · · · · · · · · · · · · · · ·			
	<u> </u>	US-				
		US-				
		US-				
		US-				

Examiner Cite Initials" No Cour		Foreign Patent Document	itent Document Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T°	
PM	AA	WO02/064789	08/22/02	Lind et al		
	AB	WO99/55733	11/04/99	Bergsma et al		
V_	AC	EP 0 913 471	05/06/99	Sathe et al		
	 					_

Examiner Signature	Penna	Menti	Date Considered	10	114	103	

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231

Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901 04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible ⁶ Applicant is to place a check mark here if English language Translation is attached

2 of 4

MAY 0 2 2000

PTO/SB/08B(10-01) Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

_	Complete if Kno	wn	a.)
Application Number	09/875,076		160°
Filing Date	June 6, 2001		,
First Named Inventor	Chen Liaw		MAY
Group Art Unit	1646	ECHO	76
Examiner Name	P. Mertz	77	Nr.
Attorney Docket Number	11.US9.DIV (A	REN-0239) 47 1d

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
PM	ВА	Standaert and Young, Treatment of Central Nervous System Degenerative Disorders, in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, Ninth Ed. (Chapter 22) pp. 503-519, 1996	i
	ВВ	Matsumoto, et al., "An Evolutionarily Conserved G-Protein Coupled rceptor Family, SREB, Expressed in the Central Nervous System," Biochem Biophys Res Comm (2000) 272.576-582	
	вс	Skolnick, et al., "Structural genomics and its importance for gene function analysis," Nature Biotechnol. (2000) 18.283-287	
			<u> </u>

Signature Considered Considered

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached.

3 of 4

PTO/SB/08a (05-03)
Approved for use through 04/30/2003 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Reguction of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

 Complete if Known

 Application Number
 09/875,076

 Filing Date
 June 6, 2001

 First Named Inventor
 C. Liaw et al.

 Art Unit
 1646

 Examiner Name
 Prema Maria Mertz

 Attorney Docket Number
 AREN-11.US9.DIV (0239)

U.S. PATENT DOCUMENTS								
Examiner Cite		Document Number	Publication Date	Name of Pateritee or Applicant of Cited Document	Pages, Columns, Lines, Where Releva			
Initials *	No '	Number - Kind Code ² (if known)	MM-DD-YYYY	Citad Document	Passages or Relevant Figures Appear			
r M		US-6,555,344 B1	04/29/2003	Matsumoto et al				
		US-						
		US-			L			
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
_ : :	Ì	US-						
	T	US-						
		US-						
		US-						
		US-						
		US-						
]	US-						
	Ī	US-						
		US-						
		US-						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*		Foreign Patent Document		Name of Patentee or	Pages Columns, Lines,				
	No No	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶			
<u>-</u>					 				
					 				
	•				<u> </u>				
		<u> </u>			 				

Examiner Signature	Brima	ment	Date Considered	10/14/03	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line trifough citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 1 Applicant's unique citation designation number (optional): 2 See Kinds Codes of USPTO Patent Documents at www.isprogov.or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3): 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1 97 and 1 98. The information is required to obtain or retain a benefit by the public which is to fife (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1 14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 1 9 2003

PTO/SB/08b(05-03)
Approved for use through 04/30/2003 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reguction Act of 1995, hopersons are required to respond to a collection of information unless it contains a valid OMB control number

C. MARK Substitute for form 1449A/PTO Complete if Known 09/875,076 **Application Number** INFORMATION DISCLOSURE June 6, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor C. Liaw et al Group Art Unit 1646 (use as many sheets as necessary) Prema Maria Mertz **Examiner Name** of 2 AREN-11 US9 DIV (0239) 2 Attorney Docket Number Sheet

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
PM		Hirsch et al., "Neuronal Vulnerability in Parkinson's Disease", J Neural Transm Suppl. 1997,50 79-88	
		Hulley et al. "Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons In Vivo* European Journal of Neuroscience, Vol. 7, pp. 2431-2440, 1995	
_ _		Berridge, Michael J., "Inositol trisphosphate and calcium signalling", Nature Vol. 361, 28 January 1993	
		Wilson et al. "Orphan G-Protein-coupled receptors" the next generation of drug targets?", British Journal of Pharmacology (1998) 125, 1387-1392	:
		Hegyi et al., "The Relationship between Protein Structure and Function: a Comprehensive Survey with Application to the Yeast Genome", <i>J. Mol. Biol.</i> (1999) 288, 147-164	
V		Kasuya et al. "Three-dimensional Structure Analysis of PROSITE Patterns". J. Mol. Biol. (1999) 286, 1673-1691	<u> </u>
	<u> </u>		

Examiner Signature	Prema	ment-	Date Considered	10	14/03	
Signature	Trovon	7	Considered	10	17.10	

^{*}EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR.1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.